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KEY POINTS
 Patients with colitis have an increased risk of developing colorectal cancer (CRC),
although the excess risk seems to be diminishing.
 Colonoscopic surveillance remains challenging because the cancer precursor (dysplasia)
can have a varied endoscopic appearance.
 The vast majority of colitic dysplasia is endoscopically visible.
 The relative frequency of different dysplasia morphologies and true clinical significance of
such lesions are difficult to determine from retrospective series, many of which were per-
formed prior to the current era of endoscopic technique and imaging.CANCER RISK
People with long-standing inflammatory bowel disease (IBD) colitis have a higher risk
of developing CRC than the general population. The most reliable estimates of this risk
come from population-based studies. The first such study, a large Swedish cohort of
long-standing ulcerative colitis (UC), found a standardized incidence ratio (SIR)
compared with the general population of 5.7 (95% CI, 4.6–7.0).1 In more recent
population-based studies of UC, the magnitude of risk seems smaller: an updated
Swedish study found an SIR of 2.3 (95% CI, 2.0–2.6),2 and one from Canada found
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Rutter328incidence or morbidity when comparing UC with the general population have in gen-
eral been limited by selection bias4 and retrospective study design.5 A recent meta-
analysis that summarizes the data from only population-based cohort studies found
the risk of CRC 2.4-fold higher in UC compared with the general population.6 Recent
evidence suggests that the CRC risk in Crohn’s colitis seems parallel to that in UC, for
the same extent of colonic involvement. In Ekbom and colleagues’ study,7 patients
with colonic Crohn had a relative risk (RR) of 5.6 (95% CI, 2.1–12.2) compared with
the general population, in contrast to those with terminal ileal Crohn, who had a risk
no different from the general population. Subsequent studies have corroborated these
findings in Crohn’s disease, reporting SIR of 2.1 (95% CI, 1.2–3.4)2 and RR 2.64 (95%
CI, 1.69–4.12).3
Various potential reasons for the apparent reduced risk of CRC over time have been
postulated, including early study selection bias, differing means of determining colitis
extent, timely colectomy, better disease (inflammation) control, a chemopreventive ef-
fect of aminosalicylate compounds, and the beneficial effect of surveillance programs.
Additional Risk Factors
Not all people with colitis have the same magnitude of CRC risk—several additional
risk factors have been identified.
Extent of inflammation
Many studies (including a systematic review) have demonstrated that an increasing
extent of mucosal inflammation correlates with increased CRC risk.1,2,5,8,9 The
measurement of disease extent has evolved over time: earliest studies used barium en-
emas, in contrast to more recent studies that have used either endoscopic (macro-
scopic) or histologic evidence. The original Swedish population-based study by
Ekbom calculated a risk in UC for CRC of 1.7 for proctitis (nonsignificant), 2.8 for left-
sided colitis, and 14.8 for pancolitis, comparedwith the general population.1 Soderlund
and colleagues’2 updated study also indicated an increased risk, albeit of lower magni-
tude, with SIR 5.6 for pancolitis, 2.1 for Crohn’s colitis, and 1.7 for proctitis—all statis-
tically significantly higher than the general population. The underlying principle
sustains—themore colonic mucosa involved, the greater the cancer risk to the patient.
Disease duration
A longer duration of colitis is associated with an increased risk of CRC. Early studies
included in 2 meta-analyses indicated an exponentially increasing CRC risk after
10 years of UC,10 with cumulative CRC risk of 2% at 10 years, 8% at 20 years, and
18% after 30 years of disease. More recent population-based studies have indicated,
however, a much lower risk, with annual incidences as low as 0.06% to 0.20% and
cumulative risk at 30 years as low as 2%.4
A Hungarian population-based study calculated a cumulative risk of 0.6% after
10 years, 5.4% after 20 years, and 7.5% after 30 years,8 and, in the largest single-
center study of colitis surveillance colonoscopy, the cumulative incidence of CRC
by colitis duration showed a linear rather than exponential increase, from 2.5% at
20 years to 10.8% at 40 years of extensive UC.11 CRC before 8 years of colitis was
thought uncommon, although a recent Swedish study calculated that 17% to 22%
of patients developed cancer before 8 to 10 years for extensive colitis and 15 to
20 years for left-sided disease.12
Severity of inflammation
IBD-CRC risk is thought to be promoted by inflammation. It is intuitive that more se-
vere inflammation may confer a higher CRC risk, but early studies showed no clear
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ever, between patients’ symptoms and the severity of inflammation, and it was only
when studies focused on severity of inflammation at a tissue level that the strong
association became apparent. A British case-control study found a significant corre-
lation between both colonoscopic (odds ratio [OR] 2.5, P<.001) and histologic (OR 5.1,
P<.001) inflammation and neoplasia risk.9 A second article on the same patient cohort
found that macroscopically normal mucosa seemed to return the CRC risk to that of
the general population.13 A subsequent American cohort study then found a signifi-
cant correlation between histologic inflammation and advanced neoplasia (hazard
ratio 3.0; 95% CI, 1.4–6.3).14
Previous inflammation
Postinflammatory polyps (PIPs), which arise during healing after severe inflammation,
have been associated with an increased CRC risk in 2 case-control studies, with ORs
of 2.14 (95% CI, 1.24–3.70)13 and 2.5 (95% CI, 1.4–4.6).15 It is thought that this prob-
ably reflects the increased risk relating to previous severe inflammation rather than the
PIPs having malignant potential per se.
Family history of CRC
As in noncolitic patients, a family history of CRC contributes to the risk of CRC in
patients with colitis. Case-control and population-based studies show a 2- to 4-fold
increase.16 An American case-control study found family history of CRC an indepen-
dent risk factor for UC-CRC (OR 3.7; 95% CI, 1.0–13.2).15 A Swedish population-
based study found that a family history of CRCwas associated with a 2.5-fold increase
in IBD-CRC (95% CI, 1.4–4.4). Where the first-degree relative was diagnosed with
CRC before 50 years of age, the risk was even higher (RR 9.2; 95% CI, 3.7–23).17
Primary sclerosing cholangitis
Primary slerosing cholangitis (PSC) seems a particularly important independent risk
factor for IBD-CRC. Although patients with PSC often have milder colonic inflamma-
tion, a meta-analysis of 11 studies concluded that patients who had both UC and PSC
were at increased risk of CRC compared with patients with UC alone (OR 4.09; 95%
CI, 2.89–5.76).18 Cancers also often occur earlier in a patient’s disease. Potential ex-
planations include that such patients may have had subclinical inflammation for many
years prior to colitis diagnosis, a deleterious effect of the altered bile salt pool, or
possible shared genetic susceptibility of PSC and CRC.
Age at diagnosis
Young age at diagnosis may be a risk factor for IBD-CRC,6 although data are incon-
sistent and may reflect other dependent factors (such as the potential for longer dis-
ease duration and more severe and extensive inflammation in younger age–onset
patients).
Ekbom and colleagues’1 population-based study found age at diagnosis an inde-
pendent risk factor for CRC. Other studies have not confirmed this association. In
Eaden and colleagues’ meta-analysis,10 a nonsignificant negative trend between
younger age at onset and increased risk of CRC was seen in adult patients, although
in children the cumulative risk of CRC was higher than the corresponding rates for
adults. In a British 30-year study, patients who developed CRC had a higher median
age of onset of disease than those not developing cancer.11 Another study found a
higher CRC risk in patients diagnosed with IBD above 30 to 40 years compared
with those diagnosed before the age of 20.19 A further study found that the time be-
tween onset of colitis and IBD-CRCwas the same in young and old patients.4 Although
Rutter330the lifetime risk and RR may be higher in those who develop colitis at a younger age,
the absolute risk of developing CRC is higher in the elderly.20
Gender
Several studies have shown that the IBD-CRC risk is greater in men than in women.6
SURVEILLANCE
Evidence for Screening/Surveillance
Surveillance colonoscopy programs aim to reduce CRCmortality (by detecting cancer
at an earlier stage with better prognosis) and where possible reduce CRC incidence
(by detecting and resecting dysplasia), while preventing unnecessary surgery. The
reduced CRC incidence seen in recent studies may be evidence that surveillance is
effective, although there are other potential explanations (described previously). Three
retrospective case-control studies have shown a correlation between the use of sur-
veillance colonoscopy and reduced OR for CRC.15,21,22 A Cochrane systematic review
on the effectiveness of surveillance23 was unable to demonstrate a benefit of surveil-
lance programs for preventing CRC-related death in UC. Only 2 studies met their
inclusion criteria, which was limited to cohort studies that included a control group.
A more recent, larger cohort study showed improved survival from colonoscopic sur-
veillance in IBD patients: 5-year CRC-related survival of patients on surveillance was
100% compared with 74% in the nonsurveillance group (P 5 .042).24 In the surveil-
lance group, 1 patient died as a consequence of CRC compared with 29 patients in
the control group (P 5 .047) and more people with early tumor stage were found in
the surveillance group (P 5 .004). All these studies could be subject to lead-time or
selection bias; thus at present, unequivocal evidence of the benefit of colitis surveil-
lance is lacking.
Because IBD-CRC tends to occur earlier in life than in the general population,
benefit estimated in years of life saved may be much greater in colitis patients: math-
ematical models of life-years saved per case screened ranges from 14 to 60 months in
UC patients compared with 1 to 4 months in general population screening.23,25
Appropriate Surveillance Strategy
Most societies recommend colonoscopic surveillance to address the increased CRC
risk. No screening program, however, can be 100% effective. The detection and treat-
ment of colorectal dysplasia in IBD remains problematic and, despite surveillance pro-
grams, patients still present with interval cancers. This may be because lesions are
missed or are incompletely excised, because patients or clinicians do not comply
with surveillance guidelines, or because aggressive de novo CRCs arise in between
surveillance procedures.
The appropriate surveillance frequency is necessarily a pragmatic balance of cost
(both financial and in terms of patient inconvenience and risk) and benefit. It is impor-
tant to focus resources on those most at risk and most likely to benefit from the pro-
gram. This is best achieved by using the established risk factors (detailed previously),
and guidelines are increasingly using these for patient risk stratification.
Because duration of disease is a major risk factor for IBD-CRC, it is rational to
commence surveillance colonoscopy when the risk starts to increase (ie, approxi-
mately 8–10 years after symptom onset).10 The subsequent surveillance interval
should take into account the risk for dysplasia development and the time it takes for
dysplasia to progress to CRC. Unfortunately, the rate of dysplasia progression in
IBD is not well established, although it undoubtedly varies between individuals. There-
fore, intervals should be adjusted to individual patients according to their CRC risk
Importance of Nonpolypoid Lesions 331factors.26 Because CRCs have been detected within 2 years of surveillance colonos-
copy, yearly colonoscopy seems appropriate for patients with high risk factors. The
appropriate frequency of surveillance for other patients is less clear.LESION CATEGORIZATION AND TERMINOLOGY
Dysplasia in Noncolitic Mucosa
Dysplastic lesions, polypoid or nonpolypoid, occurring in an area that has not been
affected by inflammation can be assumed to be sporadic adenomas unrelated to
the colitis and can be resected endoscopically.
Dysplasia Within Colitic Mucosa
Dysplasia within inflamed or previously inflamed mucosa is important because it may
progress more rapidly than adenomas in noninflamedmucosa.27 Thus, all such lesions
should be removed promptly.
Endoscopically visible colitis-associated dysplasia—polypoid dysplasia
Most dysplasia is visible during colonoscopy,28,29 and this proportion will continue to
increase with ongoing improvements in endoscopic equipment and technique.
Identification of dysplasia can be challenging, however, because it has a varied
macroscopic appearance ranging from lesions that appear identical to sporadic ade-
nomas to plaques, nodular mucosa, puckering of the mucosa, villiform mucosa, stric-
tures, and broad-based masses with indistinct lateral margins. The relative incidence
of each type of lesion has not been established in the modern era.
Raised dysplastic lesions within an area of current or previous inflammation have
been termed dysplasia-associated lesions/masses (DALMs). Early studies showed
high cancer incidences in such patients and until recently these have been considered
an indication for colectomy.30 In many cases, the lesions were actually cancers, even
though superficial mucosal biopsies did not demonstrate this endoscopically.
More recently, the term adenoma-like mass (ALM) has been used to describe
dysplastic polyps within an area of colitis, which appear endoscopically similar to spo-
radic adenomas. ALMs are well-circumscribed, sessile, or pedunculated dysplastic
polyps. Other terms used to describe these lesions have also been used, including
adenoma-like DALMs and polypoid dysplasia.
Prompt, careful, and complete endoscopic resection of so-called ALMs (including
negative biopsies taken from the normal-looking mucosa surrounding the polypec-
tomy margins) carries a good prognosis even for invisible high-grade dysplasia
(HGD), with overall rate of progression to cancer in a recent systematic review of
only 2.4%.31 If the lesion is not resectable, or is associated with dysplasia in the adja-
cent mucosa, then colectomy is appropriate due to the high risk of CRC.28,30
Unfortunately, there are no clear-cut histologic or immunohistochemical discrimina-
tors between DALMs, ALMs, and sporadic adenomas. Although some studies have
shown that villous architecture, bottom-up as opposed to top-down crypt dysplasia,
higher frequency of p53, lower frequency of KRAS mutations, and no surrounding
dysplasia are more common in ALMs, none is specific enough for clinical use. Clinical
management is thus best determined on the basis of endoscopic resectability.
Because the use of the terms DALMs and ALMs has been inconsistent, leading to po-
tential confusion and distortion of optimal management, they are best abandoned.
Lesion morphology is best described using the Paris endoscopic classification.32 A
detailed endoscopic description of morphology, including whether the lesion is well
circumscribed and whether there is background inflammation, is required.
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Flat dysplasia Many dysplastic lesions are polypoid (pedunculated or sessile and well-
circumscribed). Just as in noncolitic patients, however, some lesions are minimally
elevated (less than 2.5 mm in height, the width of closed biopsy forceps), completely
flush with the mucosa, or even depressed in morphology. These are best described
using Paris classification terminology: 0-IIa, 0-IIb, and 0-IIc lesions, respectively. To
avoid terminology confusion, clinicians should only use the term, flat, in accordance
with the Paris classification and should refrain from using the term, flat, to describe
endoscopically unapparent (invisible) dysplasia.32
Nonpolypoid lesions can be more difficult to detect, particularly where background
mucosa is inflamed or has postinflammatory changes, such as scarring or PIPs.
Optimal detection is described in the article elsewhere in this issue. Once detected,
however, many lesions may still be endoscopically resectable, after careful delineation
of the lateral margin and inspection of the surrounding mucosa.
Strictures The finding of a stricture in patients with UC is always a concern. Clinicians
should have a high index of suspicion that such strictures may harbor cancer. Even
where this is not the case, there is a greatly increased risk of subsequent cancer devel-
opment, with OR of 4.62 (95% CI, 1.03–20.8) in one case-control study.13 Because bi-
opsies may be falsely negative, surgery should be considered in such cases.Endoscopically invisible colitis-associated dysplasia
Prior to the reclassification of colitis-associated dysplasia in 1983,33 it was believed
that dysplasia occurred as a field effect.34 Based on an estimation that 33 biopsies
were required to have a 90% chance of finding the highest degree of dysplasia
present,35 a policy of taking quadrantic random biopsies every 10 cm from the color-
ectum was recommended. This policy has been poorly adhered to, however, and is
both costly and time consuming.36 Because it is now recognized that the vast major-
ity of colitic dysplasia is endoscopically visible, the recommendation to take multiple
random biopsies of mucosa should be questioned. The true value of random
biopsies has been demonstrated in the 10 prospective studies that have taken,
per protocol, quadrantic random biopsies every 10 cm from the colorectum: on
average 1 episode of dysplasia was detected for every 1505 random biopsies
taken.37 This time-consuming and expensive policy distracts endoscopists and
should be abandoned in favor of careful mucosal inspection with targeted biopsies,
aided by chromoendoscopy.
High-grade dysplasia Historical retrospective series and reviews indicate that when
endoscopically invisible HGD is detected, there are high rates either of synchronous
or metachronous cancer in 32% to 42% of patients. Thus, the general consensus
among experts recommends colectomy for these patients.38 Care must be taken
with these historical and retrospective data, however, because it is likely that many
of these lesions were not truly endoscopically invisible.
Low-grade dysplasia Where endoscopically invisible low-grade dysplasia (LGD) is
detected, management is fraught with controversy because reported rates of progres-
sion to HGD or cancer vary from as low as 0% to greater than 50%.39,40 Part of this
variability relates to the challenge histopathologists have in a discriminating neoplastic
from regenerative inflammatory changes, resulting in low interobserver agreement.41
This is why guidelines recommend all colitis dysplasia is double-reported by an expert
gastrointestinal pathologist. One recent meta-analysis revealed that the positive
predictive value for progression from nonpolypoid LGD to HGD, dysplastic mass, or
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stressed. Thus, the management decision (colectomy or surveillance) in the context of
endoscopically invisible LGD remains challenging, should take into account other fac-
tors (such as other risk factors, comorbidity, age, solitary specimen, or synchronous/
metachronous dysplasia), and should be made in conjunction with the patient and an
experienced multidisciplinary clinical team.
Indefinite dysplasia Patients with biopsy specimens that show indefinite dysplasia
have a risk of progression to HGD or CRC higher than in patients without dysplasia
but lower than for LGD. Indefinite for dysplasia is not defined by specific criteria,
and, as such, the diagnosis has high intra- and interobserver variability.SUMMARY
Patients with IBD colitis have an increased risk of developing CRC compared with the
general population. Colonoscopic surveillance remains challenging because the
cancer precursor (dysplasia) can have a varied and subtle endoscopic appearance.
Although historically the dysplasia was often considered endoscopically invisible,
today with advanced endoscopic understanding, technique, and imaging, it is almost
always visible. The frequency of different dysplasia morphologies and true clinical
significance of such lesions are difficult to determine from retrospective series,
many of which were performed prior to the current endoscopic era.REFERENCES
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